California-based AliveCor, an AI-enabled remote electrocardiogram (ECG) device manufacturer, will be collaborating with global biopharma manufacturer AstraZeneca to study disease management solutions for cardiovascular, kidney, and metabolism-related conditions.  

The partnership will use AliveCor’s Kardia-K AI technology as a non-invasive means of measuring a patient’s potassium levels, which at elevated levels can be a sign of kidney-related issues.

Founded in 2010, AliveCor develops remote patient monitoring devices under its flagship brand, KardiaMobile. The devices track a user’s heartbeat and display the results on a mobile. In November 2020, AliveCor concluded a Series E funding round that brought the company’s total funding up to USD 154.3 million.